In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symbion Health Ltd.

Division of Primary Health Care Ltd.

Latest From Symbion Health Ltd.

Shire/TKT: The Price of Diversification

Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.

BioPharmaceutical Strategy

Pliva: Two Steps Forward, One Step Back?

After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.

BioPharmaceutical Strategy

Biogenerics: A Step Closer

Progress on biogenerics inches along, as evidenced by deal between Barr Pharmaceuticals and PLIVA giving Barr rights to market Pliva's version of G-CSF in North America, and by the recent well-attended FDA workshop on follow-on proteins (FOPs). Barr/PlLIVA, the first company/company deal in this field in months indicates that companies still see opportunity despite last year's regulatory setbacks. The FDA workshop, while far from conclusive, hinted at a softening of positions by both opponents and proponents of biogenerics; at least they're talking the same language.

BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Laboratory Testing Services
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mayne Group Ltd.
  • Mayne Nickless Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Primary Health Care Ltd.
  • Senior Management
  • Robert Cooke, CEO & Managing Dir.
  • Contact Info
  • Symbion Health Ltd.
    Phone: (61) 3 9918 2000
    5 Queens Rd.
    Level 7
    Melbourne, 3004